Trials / Completed
CompletedNCT04492800
Hair Loss Prevention Study for Pancreatic Cancer
A Hair Loss Prevention Study for Patients With Advanced Pancreatic Cancer Utilizing Scalp Cooling
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 9 (actual)
- Sponsor
- HonorHealth Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Pilot study intended for hair loss prevention in patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin.
Detailed description
Patients with pancreatic cancer who are receiving treatment containing nab-paclitaxel, gemcitabine and cisplatin will experience hair preservation with the use of the Paxman scalp cooling device, at the end of three, 3 week cycles of chemotherapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Paxman Scalp Cooling Device | Cooling will consist of precooling (30 minutes); infusion cooling (will vary depending upon the length of time to infuse the chemotherapy) and post infusion cooling (90 minutes). |
Timeline
- Start date
- 2019-12-13
- Primary completion
- 2021-04-20
- Completion
- 2021-12-31
- First posted
- 2020-07-30
- Last updated
- 2022-02-24
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated device study
Source: ClinicalTrials.gov record NCT04492800. Inclusion in this directory is not an endorsement.